To include your compound in the COVID-19 Resource Center, submit it here.

Novo's oral GLP-1 analog meets in first Phase IIIa for Type II diabetes

Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) said oral semaglutide met the primary endpoint in the Phase IIIa PIONEER 1 trial to treat Type II diabetes. The candidate is on track to be the first approved oral version

Read the full 365 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers